Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
Shareholder materials challenge the board's decision to accept a proposed sale for $28 per share after previously declining an apparent $58 per‑share offer from Alcon last year. The filing is labeled as definitive proxy/additional soliciting materials and notes it is submitted under the solicitation rules; it highlights the price differential to question management and the board's judgment in pursuing the current transaction.
The document appears focused on persuading investors by contrasting the two reported offer levels and framing the board's prior choice as material to shareholders' evaluation of the transaction.
STAAR Surgical Company: Broadwood Partners filed additional proxy materials (DFAN14A) and published an investor presentation urging stockholders to vote on the GREEN Proxy Card against the proposed acquisition of STAAR by an affiliate of Alcon. Broadwood updated its campaign website on October 2, 2025 and issued a press release on October 3, 2025 linking to the materials.
Broadwood states it holds approximately 27.5% of STAAR’s outstanding common stock and cites public opposition from Yunqi Capital, which owns 5.1%. The proxy solicitation relates to the special meeting of stockholders scheduled for October 23, 2025. The definitive proxy statement and GREEN Proxy Card are available on the SEC’s website.
STAAR Surgical highlights clinical performance and market footprint for its EVO ICL product. The filing text states EVO ICL holds roughly 73% of refractive procedures in Japan, about 23% market share in China, and approximately 17% in the United States since FDA approval in 2022, with a global average above 12% of refractive procedures. The material lists product strengths including a proprietary Collamer material, EVO/EVO+ lens designs with central port technology, and single-use preloaded delivery systems. Clinical evidence cited includes a 10-year follow-up with no infections or cataracts, a large 1,800+ eye study showing strong refractive outcomes, and a 3,000+ eye systematic review reporting consistent safety and efficacy. Adverse outcomes noted: up to 85% report dry eye at one week, 27% at six months, and 41% report visual disturbances at six months; lens adjustments occur in <0.3% of cases.
Amendment No. 38 to a Schedule 13D reports that Broadwood-affiliated reporting persons collectively beneficially own 13,545,391 shares of STAAR Surgical Co., representing 27.4% of the common stock. The filing amends prior disclosures to state that on September 24, 2025 the reporting persons filed a definitive proxy statement and a GREEN proxy card to solicit votes AGAINST the Proposed Merger and the Compensation Proposal at the special meeting. The reporting persons also issued a press release and a letter to stockholders and launched the campaign website www.LetSTAARShine.com. The September 24 Letter is attached as Exhibit 99.1 and incorporated by reference.
Broadwood Partners and other investors are campaigning against STAAR Surgical’s proposed sale to Alcon at $28 per share in cash. They updated their LetSTAARShine.com website to include a CTFN article in which former STAAR CEO David Bailey argues the offer is far below earlier discussions reportedly “north of $50” per share plus a $7 performance kicker.
The article presents Bailey’s view that STAAR’s recent revenue drop reflects a temporary China disruption, not a lasting problem, and that the company’s EVO ICL lens and debt-free, cash-rich position justify a higher valuation. His and Pascal Aeschlimann’s modeling suggests standalone value of $28–$44 per share and a “right” takeover range of $50–$60, while STAAR’s board defends the $28 price as a 51% premium and stresses deal certainty.
The filing notes Broadwood and Yunqi Capital, holding 27.4% and 5.1% of STAAR shares, intend to vote against the transaction at the October 23 special meeting, framing the choice for stockholders as immediate cash versus remaining invested for potential future upside.
STAAR Surgical Company furnished an investor presentation and related press release explaining why its proposed merger with Alcon is presented as maximizing value for stockholders. These materials, dated September 26, 2025, are provided as exhibits and are described as being furnished under Regulation FD rather than filed, which limits their use in certain legal contexts. The company reminds investors that detailed information about the merger and the related vote is contained in its definitive proxy statement on Schedule 14A filed and first sent to stockholders on September 16, 2025. The communication also includes extensive forward-looking statement language outlining risks that could delay, prevent or affect the merger, such as failure to obtain stockholder or regulatory approvals, possible termination of the merger agreement, business disruption, retention of key personnel, potential legal proceedings, and stock price impacts if the transaction does not close.
STAAR Surgical proxy materials note that activist participant Broadwood launched a website, www.LetSTAARShine.com, and attached exhibits including a September 22, 2025 press release from investor Yunqi Capital and related research. The filing highlights product metrics: adoption in over 75 countries, more than 3 million implants over a 30-year period, and cost structure estimates of COGS ~29%, R&D ~9.5%, SG&A ~34%. It also cites projected market context (myopia affecting over 5 billion people by 2050) and per-share figures of $0.79 for 2025 or $1.46 if 2024 sales levels return.
STAAR Surgical Co. filed a PX14A6G disclosure containing excerpts from a 10-Q for the period ended June 27, 2025 filed on August 6, 2025. The 10-Q states that distributor inventory levels in China have decreased substantially since December 27, 2024 and returned to historical levels, and the company expects China revenue to normalize in the second half of fiscal 2025 as distributors rebuild purchases. The filing also reports a significant reduction in expenses and meaningful cost-efficiency potential, which the filer says supports a return to substantial profitability. The PX14A6G challenges the Board’s presentation of the Proposed Merger price of $28 per share, noting that while it equals ~59% and ~51% premiums to the 90-day VWAP and the closing price at announcement, it represents a ~26% discount to the 52-week high and a ~49% discount to Alcon’s prior $55 per share offer.
STAAR Surgical Co. filed a PX14A6G disclosure containing excerpts from a 10-Q for the period ended June 27, 2025 filed on August 6, 2025. The 10-Q states that distributor inventory levels in China have decreased substantially since December 27, 2024 and returned to historical levels, and the company expects China revenue to normalize in the second half of fiscal 2025 as distributors rebuild purchases. The filing also reports a significant reduction in expenses and meaningful cost-efficiency potential, which the filer says supports a return to substantial profitability. The PX14A6G challenges the Board’s presentation of the Proposed Merger price of $28 per share, noting that while it equals ~59% and ~51% premiums to the 90-day VWAP and the closing price at announcement, it represents a ~26% discount to the 52-week high and a ~49% discount to Alcon’s prior $55 per share offer.
Yunqi Path Capital Master Fund and affiliated entities disclose ownership of 2,500,061 shares of STAAR SURGICAL CO, representing 5.1% of 49,354,123 shares outstanding. The shares were acquired beginning in 2023 using the fund's working capital and, other than ordinary-course working capital borrowings, no borrowed funds were used. The reporting persons state they will vote against the proposed merger with Alcon, issued an open letter explaining their view that the merger process and price are deficient, and note a special meeting of stockholders is scheduled for October 23, 2025.
Yunqi Path Capital Master Fund and affiliated entities disclose ownership of 2,500,061 shares of STAAR SURGICAL CO, representing 5.1% of 49,354,123 shares outstanding. The shares were acquired beginning in 2023 using the fund's working capital and, other than ordinary-course working capital borrowings, no borrowed funds were used. The reporting persons state they will vote against the proposed merger with Alcon, issued an open letter explaining their view that the merger process and price are deficient, and note a special meeting of stockholders is scheduled for October 23, 2025.
Broadwood Partners and related investors have launched a proxy campaign to oppose the proposed acquisition of STAAR Surgical by Alcon. The group has filed a Schedule 13D/A and a preliminary proxy statement and plans to send a GREEN proxy card for the special meeting on October 23, 2025.
Broadwood Partners and Broadwood Capital may be deemed to beneficially own 13,519,491 STAAR shares each, and Neal C. Bradsher may be deemed to beneficially own 13,545,391 shares, together representing about 27.4% of the 49,354,123 shares outstanding as of September 12, 2025. They intend to solicit votes against both the merger agreement proposal and the advisory compensation proposal tied to the deal.
Broadwood Partners and related investors have launched a proxy campaign to oppose the proposed acquisition of STAAR Surgical by Alcon. The group has filed a Schedule 13D/A and a preliminary proxy statement and plans to send a GREEN proxy card for the special meeting on October 23, 2025.
Broadwood Partners and Broadwood Capital may be deemed to beneficially own 13,519,491 STAAR shares each, and Neal C. Bradsher may be deemed to beneficially own 13,545,391 shares, together representing about 27.4% of the 49,354,123 shares outstanding as of September 12, 2025. They intend to solicit votes against both the merger agreement proposal and the advisory compensation proposal tied to the deal.